“Characterizing Loss of Response Occurring in a Small Number of Patients During 3 Years of Long-Term Maintenance Therapy With Baricitinib 4-Mg: Results From BRAVE-AA1 and -AA2 Trials”. SKIN The Journal of Cutaneous Medicine, vol. 9, no. 1, Jan. 2025, p. s522, https://doi.org/10.25251/skin.9.supp.522.